Background and Purpose—The benefits of intravenous tissue-type plasminogen activator in
acute ischemic stroke are time dependent, and several strategies have been reported to be …

Background—The implementation of Target: Stroke Phase I, the first stage of the American
Heart Association's national quality improvement initiative to accelerate door-to-needle …

Background and Purpose—Shorter delays between symptom onset and treatment translate
into better outcomes after ischemic stroke thrombolysis. There are considerable intercenter …

Objective This study aims to investigate the effectiveness of a quality improvement program
for reducing intravenous thrombolysis (IVT) delay in acute ischemic stroke (AIS). Materials …

Background. Intravenous tissue plasminogen activator, a time dependent therapy, can
reduce the morbidity and mortality of acute ischemic stroke. This study was designed to …

Importance Given the limited time window available for treatment with tissue plasminogen
activator (tPA) in patients with acute ischemic stroke, guidelines recommend door-to …

Aims: This study aims to evaluate the implementation of a rapid response treatment protocol
for patients presenting with acute onset ischemic stroke. Improvements of routines …

Objectives To assess time trends in intravenous thrombolytic (iv tPA) treatment in a general
local hospital during a period with organizational changes, especially how movement of …

Objectives Rapid initiation of intravenous thrombolysis improves patient's outcome in acute
stroke. We analyzed inter-center variability and factors that influence the door-to-needle time …

Background: The implementation of telestroke programs has allowed patients living in rural
areas suffering from acute ischemic stroke to receive expert acute stroke consultation and …